Advertisement

Topics

Bernstein hebt Ziel für GlaxoSmithKline - 'Market-Perform'

09:25 EDT 19 Oct 2016 | FinanzNachrichten

Das US-Analysehaus Bernstein Research hat das Kursziel für GlaxoSmithKline (GSK) vor der anstehenden Berichtssaison der Pharmabranche von 1755 auf 1834 Pence angehoben und die Einstufung auf "Mark...

Original Article: Bernstein hebt Ziel für GlaxoSmithKline - 'Market-Perform'

NEXT ARTICLE

More From BioPortfolio on "Bernstein hebt Ziel für GlaxoSmithKline - 'Market-Perform'"

Quick Search
Advertisement
 

Relevant Topics

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...